These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 15326488

  • 1. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells.
    Kalaitzidis D, Ok J, Sulak L, Starczynowski DT, Gilmore TD.
    Oncogene; 2004 Sep 30; 23(45):7580-7. PubMed ID: 15326488
    [Abstract] [Full Text] [Related]

  • 2. A conditional mutant of vRel containing sequences from the human estrogen receptor.
    Capobianco AJ, Gilmore TD.
    Virology; 1993 Mar 30; 193(1):160-70. PubMed ID: 8438564
    [Abstract] [Full Text] [Related]

  • 3. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT, Reynolds JG, Gilmore TD.
    Oncogene; 2005 Nov 10; 24(49):7355-68. PubMed ID: 16027730
    [Abstract] [Full Text] [Related]

  • 4. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
    Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan ME.
    Oncogene; 2001 Oct 25; 20(48):7098-103. PubMed ID: 11704834
    [Abstract] [Full Text] [Related]

  • 5. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
    Zurovec M, Petrenko O, Roll R, Enrietto PJ.
    Oncogene; 1998 Jun 18; 16(24):3133-42. PubMed ID: 9671392
    [Abstract] [Full Text] [Related]

  • 6. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
    Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, Leeman JR, Siebert R, Gilmore TD.
    Oncogene; 2007 Apr 26; 26(19):2685-94. PubMed ID: 17072339
    [Abstract] [Full Text] [Related]

  • 7. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
    Epinat JC, Dvorin EL, Gilmore TD.
    Oncogene; 2000 Jun 29; 19(28):3131-7. PubMed ID: 10918567
    [Abstract] [Full Text] [Related]

  • 8. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S, Gilmore TD.
    Oncogene; 1993 Aug 29; 8(8):2245-52. PubMed ID: 8336947
    [Abstract] [Full Text] [Related]

  • 9. v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death.
    Zong WX, Farrell M, Bash J, Gélinas C.
    Oncogene; 1997 Aug 18; 15(8):971-80. PubMed ID: 9285692
    [Abstract] [Full Text] [Related]

  • 10. Transcriptional activation and transformation by chimaeric Fos-estrogen receptor proteins: altered properties as a consequence of gene fusion.
    Schuermann M, Hennig G, Müller R.
    Oncogene; 1993 Oct 18; 8(10):2781-90. PubMed ID: 8378087
    [Abstract] [Full Text] [Related]

  • 11. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells.
    Starczynowski DT, Reynolds JG, Gilmore TD.
    Oncogene; 2003 Oct 09; 22(44):6928-36. PubMed ID: 14534540
    [Abstract] [Full Text] [Related]

  • 12. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC, Kazandjian D, Harkness DD, Petros S, Dave J, White DW, Gilmore TD.
    Oncogene; 2000 Feb 03; 19(5):599-607. PubMed ID: 10698504
    [Abstract] [Full Text] [Related]

  • 13. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
    Fan Y, Gélinas C.
    Oncogene; 2007 Jun 07; 26(27):4038-43. PubMed ID: 17173064
    [Abstract] [Full Text] [Related]

  • 14. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
    Majid SM, Liss AS, You M, Bose HR.
    Oncogene; 2006 Feb 02; 25(5):756-68. PubMed ID: 16186799
    [Abstract] [Full Text] [Related]

  • 15. Characterization of changes in gene expression associated with malignant transformation by the NF-kappaB family member, v-Rel.
    Petrenko O, Ischenko I, Enrietto PJ.
    Oncogene; 1997 Oct 02; 15(14):1671-80. PubMed ID: 9349500
    [Abstract] [Full Text] [Related]

  • 16. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
    Gionet N, Jansson D, Mader S, Pratt MA.
    J Cell Biochem; 2009 Jun 01; 107(3):448-59. PubMed ID: 19350539
    [Abstract] [Full Text] [Related]

  • 17. The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation.
    Tong S, Liss AS, You M, Bose HR.
    Oncogene; 2007 Apr 05; 26(16):2318-29. PubMed ID: 17016434
    [Abstract] [Full Text] [Related]

  • 18. v-Myb represses the transcription of Ets-2.
    Wang DM, Sevcikova S, Wen H, Roberts S, Lipsick JS.
    Oncogene; 2007 Feb 22; 26(8):1238-44. PubMed ID: 16909100
    [Abstract] [Full Text] [Related]

  • 19. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
    Maru BS, Tobias JH, Rivers C, Caunt CJ, Norman MR, McArdle CA.
    Bone; 2009 Jan 22; 44(1):102-12. PubMed ID: 18976723
    [Abstract] [Full Text] [Related]

  • 20. Estrogen receptor inhibits interleukin-6 gene expression by disruption of nuclear factor kappaB transactivation.
    Liu H, Liu K, Bodenner DL.
    Cytokine; 2005 Aug 21; 31(4):251-7. PubMed ID: 16043358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.